Current Report Filing (8-k)
October 01 2018 - 5:30PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 1, 2018
MICROBOT
MEDICAL INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-19871
|
|
94-3078125
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
25
Recreation Park Drive, Unit 108
Hingham,
Massachusetts 02043
(Address
of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code: (781) 875-3605
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
Growth Company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01
|
Regulation
FD Disclosure.
|
On
October 1, 2018, Microbot Medical Inc. (the “Registrant”) issued a press release announcing that Harel Gadot, Chief
Executive Officer, President and Chairman of the Company, is scheduled to present on Tuesday, October 2, 2018 at 1:30 P.M. (ET)
at the Ladenburg Thalmann Healthcare Conference, at the Sofitel Hotel in New York City. A live webcast and subsequent archived
replay of the Company’s presentation may be accessed via the ‘Investors’ section, under ‘Presentations
and Resources’ of the Company’s website at www.microbotmedical.com. A copy of the press release is furnished as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company is also furnishing presentation
materials as Exhibit 99.2 to this Current Report on Form 8-K. The Company is not undertaking to update this presentation.
The
information in this Item 7.01 and in Exhibits 99.1 and 99.2 of Item 9.01 is being furnished pursuant to Item 7.01 and shall
not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any
information in this Item 7.01 or Exhibits 99.1 and 99.2 of Item 9.01.
Item
9.01
|
Financial
Statements and Exhibits.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
MICROBOT
MEDICAL INC.
|
|
|
|
By:
|
/s/
Harel Gadot
|
|
Name:
|
Harel
Gadot
|
|
Title:
|
President,
Chief Executive Officer and Chairman
|
Date:
October 1, 2018
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Sep 2023 to Sep 2024